LAG-3 Protein/Pembrolizumab Yield Encouraging Responses in Metastatic HNSCC
The median duration of response (DOR) was not reached with 4 events (40%) at a median follow-up of 38.8 months. Additionally, the 12-month and 24-month DOR rates, respectively, were 80.0% and 60.0% in the ITT population. The soluble LAG-3 protein eftilagimod alpha plus pembrolizumab (Keytruda) demonstrated encouraging responses and was well tolerated in patients with … [Read more…]
